Skip to main content

Animations

Illustrated close up of DNA.

Research Tools Catalog

To save researchers time and resources, The Michael J. Fox Foundation has made a number of tools available to the scientific community at low cost, with rapid delivery.

Helpful Resources

  • Illustrated adjacent hexagons.

    Sponsored Tools Program

    Learn more about how MJFF can help share your tools.

  • Illustrated Parkinson's Disease Research Tools Consortium logo.

    Tools Consortium

    MJFF is working with industry to develop priority tools.

  • Illustrated brain on a presentation display.

    Preclinical Models

    Learn more about the various in vivo models used in Parkinson's disease research.

Find a Research Tool

Filter by Tool Type or Gene/Protein Type to Organize Results

* = MJFF does not control pricing or terms of availability for this tool. 

Filters
Sort options
Sort by
Order
Filters
Sort options
Sort by
Order
Sort options
Sort by
Order
Results (277)
Sort by:
Alpha-Synuclein A53T Knockin Rat
Rat Model
CRISPR/Cas9 genome targeting strategy to knockin humanized amino acids for A53T on a Sprague Dawley rat aSyn KO background. RRID:RGD_13782163 Generated as part of the Industry Tools Consortium. 
  • Alpha-Synuclein
Alpha-Synuclein KO Rat
Rat Model
Sprague Dawley rat strain with CRISPR/Cas9 genome targeting strategy to KO endogenous alpha-synuclein. Generated as part of the Industry Tools Consortium.
  • Alpha-Synuclein
AAV1/2-CAG-Human SNCA 3xmiR/GFP
Viral Vector
CNS optimized viral vector (AAV1/2 pseudotype) encoding GFP and 3XmiR to alpha-synuclein for specific knockdown of WT human a-syn and common pathogenic mutant forms (A53T, A30P, E46K). Scrambled Control 3xSCRmiR/GFP available as a control in Reporter section and AAV Human SNCA 3xmiR/GFP plasmid available in the Plasmid section.  Generated as part of the Industry Tools Consortium.
  • Alpha-Synuclein
AAV1/2-CAG-Mouse SNCA 3xmiR/GFP
Viral Vector
CNS optimized viral vector (AAV1/2 pseudotype) encoding GFP and 3XmiR to alpha-synuclein for specific knockdown of WT mouse a-syn and common pathogenic mutant forms (A53T, A30P, E46K).  Scrambled Control 3xSCRmiR/GFP available as a control in Reporter section and AAV Mouse SNCA 3xmiR/GFP plasmid available in the Plasmid section.  Generated as part of the Industry Tools Consortium.
  • Alpha-Synuclein
AAV1/2-CAG-Scrambled Control 3xSCRmiR/GFP
Viral Vector
CNS optimized viral vector (AAV1/2 pseudotype) encoding GFP and a scrambled control 3XmiR. To be used as a control vector with Mouse SNCA 3xmiR/GFP and Human SNCA 3xmiR/GFP. AAV 3xSCRmiR/GFP plasmid is available in the Plasmid section. Generated as part of the Industry Tools Consortium.
  • Control
Alpha-Synuclein Filament-Specific Antibody
Antibody
Conformation-specific rabbit monoclonal antibody directed against the filamentous form of wild-type alpha-synuclein.
  • Alpha-Synuclein
Full Length pS129 Alpha-Synuclein Protein
Protein
Phospho-S129 Alpha Synuclein semi-synthetic phosphomimetic protein generated by native chemical ligation of a recombinant peptide produced from E. coli and a synthtic peptide
  • Alpha-Synuclein
LRRK2 D1994A/G2019S Mouse
Mouse Model
Transgenic mice overexpressing both a mutant form D1994A and G2019S of human LRRK2 directed by its endogenous promoter/enhancer regions on the BAC transgene. Please note: Although founders were positively identified through genotyping and exhibited robust mRNA expression, these projects were halted due to a lack of any appreciable protein expression.
  • LRRK2
LRRK2 D1994A/R1441G Mouse
Mouse Model
Transgenic mice overexpressing both a mutant form D1994A and R1441G of human LRRK2 directed by its endogenous promoter/enhancer regions on the BAC transgene. Please note: Although founders were positively identified through genotyping and exhibited robust mRNA expression, these projects were halted due to a lack of any appreciable protein expression.
  • LRRK2
EIF4G1 R1207H Mouse
Mouse Model
Mice expressing the R1207H mutant form of EIF4G1. RRID:IMSR_JAX:021827
  • EIF4G1
Have questions or need additional information?

Email tools@michaeljfox.org with questions and to suggest new tools for us to develop. Or visit our FAQ page. 

"We have shown, thanks in part to MJFF, that researchers now have in their pantry the right ‘ingredients’, to... help to drive forward PD drug development.”
Heather Melrose, PhD Mayo Clinic
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.